NASDAQ · Biotechnology

CTMX (CTMX) Stock

$3.37 +4.01% NASDAQ: CTMX Healthcare

Valuation

MetricValue
Price$3.37
Market Cap$541.98M
P/E Ratio-24.27
P/B Ratio5.91
P/S Ratio17.17
EPS (TTM)$0.00
52-Week High$8.21
52-Week Low$1.72
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-17.17%
ROA-11.18%
ROCE-22.22%
Gross Margin-30.26%
Operating Margin-28.95%
Net Margin-1.66%
Debt/Equity0.01
Current Ratio3.06

Annual Financials (USD)

Metric20212022202320242025
Revenue$37.0M$53.0M$101.0M$138.0M$76.0M
Operating Profit$-116.0M$-101.0M$-6.0M$25.0M$-22.0M
Net Profit$-116.0M$-99.0M$-1.0M$32.0M$-17.0M
EPS$-1.26$-1.48$-0.01$0.38$-0.15
Op Margin-311.0%-190.6%-6.4%18.1%-29.4%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$339.0M$261.0M$202.0M$121.0M$152.0M
Total Liabilities$340.0M$347.0M$249.0M$121.0M$53.0M
Cash$206.0M$194.0M$17.0M$38.0M$13.0M
Borrowings$22.0M$18.0M$14.0M$9.0M$4.0M

Latest News

CytomX Therapeutics (CTMX) Upgraded to Buy: Here's Why Zacks · Jul 8, 2026 Is CytomX (CTMX) One of the Best Growth Stocks Under $30 to Buy Now? Insider Monkey · Jun 19, 2026 How The Narrative Around CytomX Therapeutics (CTMX) Is Evolving With Recent Developments Simply Wall St. · Jun 11, 2026 A Look At Regeneron Pharmaceuticals (REGN) Valuation After Expanded CytomX Partnership And Positive Lynozyfic Trial Results Simply Wall St. · Jun 5, 2026 REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics Zacks · Jun 4, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-119.0M$-111.0M$-56.0M$-86.0M$-76.0M
Investing Cash Flow$21.0M$97.0M$-152.0M$99.0M$-60.0M
Financing Cash Flow$3.0M$0$0$1.0M$0
Net Cash Flow$14.0M$-12.0M$-176.0M$21.0M$-25.0M
Free Cash Flow$-121.0M$-113.0M$-57.0M$-87.0M$-76.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA—
FCF Yield-13.14%
Quick Ratio10.38
Interest Coverage—
Return 1Y37.04%
Return 3Y90.29%
Return 5Y-37.76%

Ownership

Insiders Held0.53%
Institutions Held96.42%
Institutions Float Held96.93%
Institutional HolderSharesReport Date
FMR, LLC31,955,6372026-03-31
Kynam Capital Management, LP15,013,0932026-03-31
Bank of America Corporation10,202,7852026-03-31
Perceptive Advisors Llc10,098,8242026-03-31
Venrock Adviser, LLC9,982,1242026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ATXSAstria Therapeutics, Inc. $12.58 +0.00% -7.40 $718.13M 0.00%
AVBP $30.84 -0.55% -8.82 $1.44B 0.00%
AVXL $2.49 -3.11% -5.02 $230.75M 0.00%
DNA $8.07 -0.19% -1.30 $527.50M 0.00%
ERAS $17.72 -2.42% -23.45 $6.15B 0.00%

About CTMX

CTMX is led by CEO Sean A. McCarthy, employs 119 people, headquartered in US, publicly traded since 2015.

CTMX stock trades at $3.37 with a market capitalization of $541.98M. The stock is valued at a price-to-earnings (P/E) ratio of -24.27, price-to-book of 5.91, price-to-sales of 17.17. Over the past 52 weeks the stock has ranged between $1.72 and $8.21, and currently trades 59.0% below its 52-week high.

On profitability, CTMX generates a return on equity (ROE) of -17.17%, return on capital employed of -22.22%, an operating margin of -28.95%, a net profit margin of -1.66%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides